InformationInformation Center

Hualan Bio Acquiring the Clinical Approval Document of Recombinant Exendin-4-Fc Fusion Protein Injection

Hualan Bio Acquiring the Clinical Approval Document of Recombinant Exendin-4-Fc Fusion Protein Injection

On September 17, 2020, Hualan Biological Engineering Inc. received the clinical approval document of “Recombinant Exendin-4-Fc Fusion Protein Injection” issued by the National Medical Products Administration, with the approval number of 2020LP00444. The indications of Recombinant Exendin-4-Fc Fusion Protein Injection are: assisting the therapy of diet and exercise to improve the control of blood glucose for the patients with Type 2 diabetes.

According to the drug registration procedure, Hualan Biological Engineering Inc. will organize the clinical trials as soon as possible in accordance with the requirements of national drug clinical trials after acquiring the clinical approval document of Recombinant Exendin-4-Fc Fusion Protein Injection, and Hualan Biological Engineering Inc. will apply the product production approval documents and GMP certificate after completing the clinical trials.

Hualan | Hualan Biological

 


TAG:  Hualan Bio, Recombinant Exendin-4-Fc Fusion Protein Injection, Type 2 diabetes, Blood Glucose Control, Clinical Approval Document